AMARIN CORP PLC\UK Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
AMARIN CORP PLC\UK (AMRN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.49 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2024-02-29
- AMARIN CORP PLC\UK valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $3.49M, a 73.00% decline from fiscal 2022.
- AMARIN CORP PLC\UK valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $12.94M, a 346.43% increase from fiscal 2021.
- AMARIN CORP PLC\UK valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $2.90M, a 76.72% decline from fiscal 2020.
- AMARIN CORP PLC\UK valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $12.45M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2023-12-31 | $3.49M 10-K · filed 2024-02-29 |
| 2022-12-31 | $12.94M 10-K · filed 2024-02-29 |
| 2021-12-31 | $2.90M 10-K · filed 2023-03-01 |
| 2020-12-31 | $12.45M 10-K · filed 2022-03-01 |
| 2019-12-31 | -$114.00K 10-K · filed 2021-02-25 |
| 2018-12-31 | $13.61M 10-K · filed 2020-02-25 |
| 2017-12-31 | $11.47M 10-K · filed 2019-02-27 |
| 2016-12-31 | $17.95M 10-K · filed 2018-02-27 |
| 2015-12-31 | $16.29M 10-K · filed 2017-03-01 |
| 2014-12-31 | $5.08M 10-K · filed 2016-02-25 |
| 2013-12-31 | $33.00M 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |